Strata Oncology Announces Launch and Medicare Coverage for Strata Select, a First-of-its-kind Immunotherapy Test (PRNewswire)
"Strata Oncology, Inc...today announced the launch of Strata Select™, a first-of-its-kind molecular profiling test for patients with advanced cancer. The new diagnostic test features the Immunotherapy Response Score, a novel multivariate predictive biomarker algorithm for anti-PD-1/PD-L1 checkpoint inhibitor immunotherapy benefit....The Immunotherapy Response Score integrates relevant biological factors (TMB, PD-L1, PD-1, and tumor microenvironment components) into a simple score to predict immunotherapy benefit across all solid tumors."